Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 992-994

  Salmon, Héléne ^a   Donnadieu, Emmanuel ^a  

^a INSTITUT COCHIN   (France)

Author keywords

Chemokines; Extracellular matrix; Human lung tumor; Migration; Stroma; T lymphocyte

Indexed keywords

CAVEOLIN 1; CHEMOKINE; COLLAGEN; ENZYME INHIBITOR; FIBRONECTIN; PROTEIN LYSINE 6 OXIDASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL INTERACTION; DENDRITIC CELL; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; LYMPHOID ORGAN; NONHUMAN; PRIORITY JOURNAL; STROMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886944141     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20239     Document Type: Article

References (10)

1. Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7:4; PMID:17311363.
2. Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012; 122:899-910; PMID:22293174; http://dx.doi.org/10.1172/JCI45817.
3. Pivarcsi A, Müller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci USA 2007; 104:19055-60; PMID:18025475; http:// dx.doi.org/10.1073/pnas.0705673104.
4. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208:1949-62; PMID:21930770; http://dx.doi.org/10.1084/jem.20101956.
5. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284.
6. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196:395-406; PMID:22351925; http://dx.doi. org/10.1083/jcb.201102147.
7. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139:891-906; PMID:19931152; http://dx.doi.org/10.1016/j.cell.2009.10.027.
8. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA 2011; 108:2909-14; PMID:21282607; http://dx.doi.org/10.1073/pnas.1018892108.
9. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21:418- 29; PMID:22439937; http://dx.doi.org/10.1016/j.ccr.2012.01.007.
10. Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011; 146:148- 63; PMID:21729786; http://dx.doi.org/10.1016/j.cell.2011.05.040.